Circulating tumor DNA and circulating tumor cells as predictor of outcome in the PRODIGE14-ACCORD21-METHEP2 phase II trial

Bidard, François-Clément; Bouche, O.; Cacheux,, W.; Francois, E.; Ghiringhelli, François; Guimbaud, R.; Khemissa-Akouz, F.; Madic, J.; Mariani, P.; Mazard, T.; Mineur, L.; Moussata, D.; Pierga, J-Y.; Proudhon,, C.; Rivoire, M.; Saliou, A.; Stanbury, T.; Stern, M-H.; Thezenas, S.; Ychou, M.

Circulating tumor DNA and circulating tumor cells as predictor of outcome in the PRODIGE14-ACCORD21-METHEP2 phase II trial

Authors: François-Clément Bidard
O. Bouche
Cacheux,W.
E. Francois
François Ghiringhelli
R. Guimbaud
F. Khemissa-Akouz
J. Madic
P. Mariani
T. Mazard
L. Mineur
D. Moussata
J-Y. Pierga
Proudhon,C.
M. Rivoire
A. Saliou
T. Stanbury
M-H. Stern
S. Thezenas
M. Ychou
Publication date: 1 October 2016
Publisher: 'Oxford University Press (OUP)'
Doi

Abstract

IF 9.269International audienceBackground: We prospectively detected circulating tumor DNA (ctDNA) and circulating tumor cells (CTC) levels in patients (pts) included in the PRODIGE14-ACCORD21-METHEP2 randomized phase II trial.Methods: The trial enrolled colorectal cancer pts with potentially resectable liver metastases & no prior treatment; the primary endpoint was the rate of R0/R1 liver metastases resection achieved by 1st line regimen (targeted therapies & bi- vs tri-chemotherapy; Ychou, ASCO 2016). Blood samples were collected at inclusion, after 1 month of therapy and before any liver metastases surgery. CTCs (CellSearch) & ctDNA (ddPCR, BioRad) were detected in an experienced laboratory (Inst. Curie).Results: 153 pts had at least one blood analysis. High CTC count (≥3 CTC/7.5ml) was detected in 25/132 pts (19%) at baseline and associated with synchronous..